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Summary
Mutations in the FBN1 gene, which encodes fibrillin-1,
causeMarfan syndrome (MFS) and have been associated
with a wide range of milder, overlap phenotypes. The
factors that modulate phenotypic severity, both between
and within families, remain to be determined. This study
examines the relationship between the FBN1 genotype
and phenotype in families with extremely mild pheno-
types and in those that show striking clinical variation
among apparently affected individuals. In one family,
clinically similar but etiologically distinct disorders are
segregating independently. In another, somatic mosai-
cism for a mutant FBN1 allele is associated with sub-
diagnostic manifestations, whereas germ-line transmis-
sion of the identical mutation causes severe and rapidly
progressive disease. A third family cosegregates mild mi-
tral valve prolapse syndrome with a mutation in FBN1
that can be functionally distinguished from those asso-
ciated with the classic MFS phenotype. These data have
immediate relevance for the diagnostic and prognostic
counseling of patients and their family members.
Introduction
Marfan syndrome (MFS; MIM 154700) is a systemic
disorder of connective tissue, with autosomal dominant
inheritance and a prevalence of ∼1/5,000–10,000 indi-
viduals (reviewed in Pyeritz 1993). The cardinal features
of MFS involve the ocular, skeletal, and cardiovascular
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systems. The syndrome shows complete penetrance but
is notable for variability in the timing of onset, tissue
distribution, and severity of clinical manifestations, both
between and within affected families. The ability to
study the molecular determinants of phenotypic varia-
tion have become possible only since the identification
of the fibrillin-1 gene (FBN1) as the site of primary mu-
tations (Dietz et al. 1991; reviewed in Dietz and Pyeritz
1995). Fibrillin-1 monomers associate to form complex
extracellular macroaggregates, termed “microfibrils,”
that are important for the integrity and homeostasis of
both elastic and nonelastic tissues (Sakai et al. 1986;
Pereira et al. 1997).
Mutations in FBN1 have been associated with a broad
spectrum of phenotypes (reviewed in Dietz and Pyeritz
1995). The severe end of this clinical continuum is de-
fined by a rapidly progressive form of MFS that presents
at birth and that is associated with significant functional
impairment and often death in early childhood. So-called
classic MFS is a highly variable condition with pleiotro-
pic manifestations in the eye (myopia and lens disloca-
tion), skeleton (bone overgrowth and joint laxity), car-
diovascular system (mitral valve prolapse and aortic
dilatation and dissection), skin (striae distensae), and
integument (hernia and dural ectasia). Conditions at the
mild end include the MASS (mitral valve prolapse, bor-
derline and nonprogressive aortic dilatation, and skin
and skeletal manifestations) phenotype (MIM 157700),
mitral valve prolapse syndrome (MIM 157700), isolated
dolichostenomelia, predominant aortic aneurysm (MIM
132900), and ectopia lentis (MIM 129600) with rela-
tively mild skeletal features. Because of the high popu-
lation frequency and nonspecific nature of many of the
clinical findings in MFS, clinical diagnostic criteria for
this disorder have been established (De Paepe et al.
1996).
In this study, we examined the FBN1 genotype and
cellular phenotype in families segregating MFS with
marked intrafamilial clinical variability or with mild
phenotypes that failed to meet diagnostic criteria for this
disorder. Multiple molecular mechanisms, including so-
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matic mosaicism and allelic and locus heterogeneity,
were identified as determinants of clinical expression.
Subjects and Methods
Subjects
This study was approved by an institutional review
board, and informed consent was obtained. All partic-
ipants were evaluated by a multidisciplinary team, in-
cluding a medical geneticist, a cardiologist, and an oph-
thalmologist. Data obtained included family history,
physical examination, and the results of echocardio-
graphy and slit-lamp examination. Control subjects for
the population screening of mutation R1170H were un-
related and of Irish descent. Samples had been sent to a
DNA diagnostic facility for the consideration of phe-
notypes other than MFS or for other heritable disorders
of connective tissue. We remain unaware of the identity
of these individuals.
Linkage Analysis
Linkage analysis was performed by use of microsat-
ellite markers within the FBN1 gene. The primer se-
quences and assay conditions have been described else-
where (Pereira et al. 1994). Haplotypes were generated
by observing for combinations of marker alleles that
segregated as a unit.
Mutation Identification and Population Screening
PCR amplification of individual exons of FBN1, het-
eroduplex analysis, and DNA sequencing were per-
formed by use of primer sequences and conditions that
have been described elsewhere (Nijbroek et al. 1995).
Population screening for mutations C1265R, R1170H,
and R529X was performed by use of restriction enzymes
Cac8I, MscI, and DdeI, respectively. All restriction en-
zymes were used in accordance with protocols supplied
by the manufacturer (New England Biolabs).
Quantification of Mutant Transcript
RNA extraction, reverse-transcription PCR, and al-
lele-specific oligonucleotide (ASO) hybridization analy-
sis for mutation R529X were performed by use of stan-
dard procedures, without modification (Dietz et al.
1992). The primers used to amplify fibroblast or lym-
phoblast cDNA were FB5S (5′-TTACCGGTGTGAGT-
GCAAC-3′) and FB5AS (5′-AGGAGCCATCAGTGTT-
GAC-3′). The probes used for ASO analysis were R529-
WT (5′-ACGCGGACAGAATGCCGAG-3′) and X529-
MUT (5′-CTCAGCATTCTGTCCGCGT-3′). The final
wash temperature for both probes was 62C. Signal
strength was quantified by use of the INSTANTIMA-
GER system (Packard Instrument). A correction factor
was calculated in order to equalize the wild-type and
mutant signals observed after sequential hybridization
of the probes to PCR-amplified genomic DNA from an
individual who had inherited R529X through germ-line
transmission. This served to adjust for varying affinity
of the two probes for their target sequences. This same
correction factor was applied when determining the rel-
ative amount of wild-type and mutant signals in genomic
DNA from an individual mosaic for R529X and in PCR-
amplified cDNA.
As an alternative method for determination of the
degree of mosaicism in the mother of the proband
harboring R529X, genomic DNA derived from fibro-
blasts or from lymphoblasts was amplified with prim-
ers exon12S (5′-AGAATTATGAGGTATTGCTATG-3′)
and exon12AS (5′-CAGTTAGCATATATGTCCCAC-3′).
Cold and radioactive dCTP were included in the reaction
mix, at final concentrations of 20 mM and 0.25 mM,
respectively. The experiment was executed with 20, 25,
and 30 cycles of amplification. Amplicons were digested
with DdeI and were electrophoresed on an 8% poly-
acrylamide gel. The signal strength of each restriction
fragment was measured by use of the INSTANT-
IMAGER system.
Immunohistochemistry
Cell culture and immunohistochemical analysis were
performed by use of procedures and reagents described
elsewhere (Eldadah et al. 1995). Chamber slides were
seeded with cells from each culture and were52# 10
grown for 72 h, prior to analysis. At this point all
cultures had reached a comparable degree of cell den-
sity, as was confirmed by direct visualization and cell
counting.
Results
Intrafamilial Genetic Heterogeneity
The proband (I-1) of the pedigree shown in figure 1A,
who is now 32 years of age, was diagnosed with MFS
in late adolescence because dolichostenomelia, arach-
nodactyly, pes planus, bilateral superior lens subluxa-
tion, and significant and progressive aortic root dilata-
tion were found. Her eldest child (II-1) was 12 years of
age and showed many suggestive features of a connec-
tive-tissue disorder, including a decreased upper-to-lower
segment ratio (0.84), increased arm span–to-height ratio
(1.05), arachnodactyly (middle-finger length 197%), a
narrow and elongated face, pes planus, and an aortic
annulus measurement that was 2.37 SDs above the
mean, when standardized to age and body surface area.
Aortic measurements at the sinuses of Valsalva, sino-
tubular junction, and ascending aorta were within nor-
mal limits. There was no pectus deformity, scoliosis, joint
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Figure 1 Analysis of mutation C1265R. A, Pedigree of a family displaying a heritable disorder of connective tissue. Blackened symbols
indicate individuals with significant skeletal involvement and dilatation of the aortic root, with (I-1) or without (II-4) lens dislocation; hatched
symbols indicate individuals with significant skeletal involvement and isolated dilatation of the aortic annulus (II-1) or of the ascending aorta,
distal to the root (II-3); and unblackened symbols indicate no features of a connective-tissue disorder. Numbers designating FBN1 haplotypes
are shown below each symbol. The results of restriction analysis for mutation C1265R are shown below the pedigree. The appearance of 193-
bp and 99-bp restriction fragments manifests the presence of mutation C1265R. B, Sequence of PCR-amplified genomic DNA from individual
I-1, showing a TrC transition at nucleotide 3793 in one allele. The exon sequence and the corresponding amino acid sequence of the normal
and mutant alleles in the region of the mutation are shown (bottom), demonstrating a substitution of arginine (“Arg”) for cysteine (“Cys”) at
codon 1265.
laxity, myopia, lens dislocation, or mitral valve prolapse.
Three younger children were born to a different father
(I-2). The eldest child (II-2) was 6 years of age and had
an entirely normal physical exam, ophthalmology eval-
uation, and echocardiographic study. II-3 was 4 years
of age and had a normal upper-to-lower segment ratio
(1.17) but a mildly increased arm span–to-height ratio
(1.04). He also had pes planus and pectus excavatum
deformity but no arachnodactyly. He did not have my-
opia or lens dislocation. The echocardiogram showed a
normal size for the aortic annulus and aortic root at the
level of the sinuses of Valsalva. Dilatation of the aorta
began at the sinotubular junction and extended through
the ascending aortic arch (2.05 and 2.50 SDs, respec-
tively, above the mean). There was no significant val-
vular regurgitation and no mitral valve prolapse. He had
normal visual acuity, without lens dislocation. The
youngest child (II-4) was 2 years of age. He had a normal
upper-to-lower segment ratio of 1.06, an increased arm
span–to-height ratio of 1.05, arachnodactyly, joint lax-
ity, and malar hypoplasia. An echocardiogram revealed
myxomatous mitral leaflets but no mitral valve prolapse
or regurgitation. The aortic annulus, root, sinotubular
junction, and ascending segment were significantly di-
lated (2.95, 5.78, 4.64, and 2.18 SDs, respectively, above
the mean). There was no lens dislocation. Prior to mo-
lecular analysis, the referring physician had diagnosed
the mother and her two youngest children (II-3 and II-
4) with MFS. Despite the fact that the findings for the
oldest child (II-1) were somewhat atypical and nonspe-
cific, the diagnosis of MFS was strongly considered,
because of the clinical presentation of other family
members.
Haplotype segregation analysis using four intragenic
microsatellite polymorphic markers revealed that the
proband and her three apparently affected children did
not all share a common FBN1 allele (fig. 1A). Hetero-
duplex analysis of a genomic amplicon from the pro-
band, spanning exon 30 of the FBN1 gene, demonstrated
an abnormally migrating fragment (data not shown).
Direct sequencing of this amplicon revealed a TrC tran-
sition at nucleotide 3793 of the fibrillin-1 coding se-
quence, predicting the substitution of arginine (R) for
cysteine (C) at codon 1265 (fig. 1B), within a calcium-
binding epidermal growth factor–like (cbEGF-like) do-
main of fibrillin-1. Mutation C1265R creates a restric-
tion site for enzymeCac8I, cleaving the 292-bp amplicon
into fragments of 193 bp and 99 bp. Restriction analysis
revealed that the proband (I-1) and her son with classic
distribution of aortic involvement (II-4) carry this mu-
tation, whereas her two sons with significant skeletal
involvement but atypical vascular manifestations (II-1
and II-3) and her unaffected daughter (II-2) do not (fig.
1A).
“Conservative” Mutation in FBN1
The proband (II-3) of the pedigree shown in figure
2A, who is now 46 years of age, was diagnosed with a
nonspecific connective-tissue disorder because dolichos-
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Figure 2 Analysis of mutation R1170H. A, Pedigree of a family displaying a heritable disorder of connective tissue. The key for the
assignment of clinical features to each individual is shown below the pedigree. The proband (II-3) is indicated by an arrow. The FBN1 genotype
is shown immediately below each symbol, with a plus sign () denoting the presence of R1170H on one allele. B, Sequence of PCR-amplified
genomic DNA from individual II-3, showing a GrA transition at nucleotide 3509 in one allele. The exon sequence and the corresponding
amino acid sequence of the normal and mutant alleles in the region of the mutation are shown (bottom), demonstrating a substitution of
histidine (“His”) for arginine (“Arg”) at codon 1170. C, Results of restriction analysis for mutation R1170H. The appearance of 127-bp and
98-bp restriction fragments manifests the presence of mutation R1170H.
tenomelia, joint hypermobility, kyphoscoliosis, pes
planus, positive wrist and thumb signs, striae distensae,
early myopia, and myxomatous mitral leaflets with mi-
tral valve prolapse were found. There was no lens dis-
location, and all aortic measurements were within nor-
mal limits, when standardized to age and body surface
area. As shown in figure 2A, multiple family mem-
bers—including all four of the proband’s children and
her brother, father, and paternal uncle—had a tall, thin
body habitus and/or preadolescent myopia. Two indi-
viduals, the proband’s father (I-2) and eldest son (III-2),
showed more-specific findings, including arachnodac-
tyly, dolichostenomelia, pectus deformity, scoliosis, pos-
itive wrist and thumb signs, and mitral valve prolapse.
Like the proband, neither of these individuals had lens
dislocation or aortic dilatation. Although no individual
in this family satisfied the diagnostic criteria for MFS
(De Paepe et al. 1996), the proband and her father and
eldest son likely share a mutant allele that caused an
autosomal dominant disorder of connective tissue.
Heteroduplex analysis of a genomic amplicon from
the proband, spanning exon 28 of the FBN1 gene, dem-
onstrated an abnormally migrating fragment (data not
shown). Direct sequencing of this amplicon revealed a
GrA transition at nucleotide 3509 of the fibrillin-1 cod-
ing sequence, predicting the substitution of histidine (H)
for arginine (R) at codon 1170 (fig. 2B), within a cbEGF-
like domain of fibrillin-1. Mutation R1170H creates a
restriction site for enzyme MscI, cleaving the 225-bp
amplicon into fragments of 127 bp and 98 bp. Restric-
tion analysis revealed that all family members with sig-
nificant skeletal involvement and mitral valve prolapse
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carry this mutation, whereas individuals with only mild
and nonspecific findings do not (fig. 2C). The proband’s
father was of Irish descent. We screened 100 samples,
obtained from unrelated Irish individuals, that were sent
to a DNA diagnostics facility for evaluation of a diag-
nosis other than MFS. Restriction analysis and sequenc-
ing revealed that only one patient, who was referred in
order to rule out fragile X syndrome, was heterozygous
for R1170H (data not shown). Although we were
blinded to the identity of this individual, we know that
the diagnosis of fragile X was excluded. No further in-
formation was available.
Somatic Mosaicism
The proband of the third family (fig. 3B) was diag-
nosed with MFS at 24 years of age, when an echocar-
diogram revealed dilatation of the aortic root, to 8 cm,
and chronic ascending aortic arch dissection. Associated
features included preadolescent myopia, dolichosteno-
melia, asymmetric pectus carinatum deformity, scoliosis,
joint hypermobility, pes planus, and widespread striae
distensae. There was no lens dislocation. The proband’s
mother, who is now 60 years of age, showed only joint
hypermobility, pes planus, and striae distensae over the
abdomen and trunk. There was no myopia or lens dis-
location, and all aortic measurements were within nor-
mal limits, when standardized to age and body surface
area. There was no other family history suggestive of a
connective-tissue disorder.
Heteroduplex analysis of a genomic amplicon from
the proband, spanning exon 12 of the FBN1 gene, dem-
onstrated an abnormally migrating fragment (data not
shown). Direct sequencing of this amplicon revealed a
CrT transition at nucleotide 1585 of the fibrillin-1 cod-
ing sequence, predicting the substitution of a premature-
termination codon (X) for arginine (R) at codon 529
(fig. 3A), within a cbEGF-like domain of fibrillin-1. Mu-
tation R529X creates a restriction site for enzyme DdeI,
cleaving the 223-bp amplicon into fragments of 170 bp
and 53 bp. Remarkably, restriction analysis of PCR-am-
plified genomic DNA derived from lymphoblasts re-
vealed that both the classically affected proband and his
apparently unaffected mother harbor this nonsense mu-
tation (fig. 3B). The decrease in intensity of the abnormal
restriction fragment in the mother, relative to that seen
in her son, suggests that she might be a somatic mosaic
for mutation R529X. This hypothesis was tested by ASO
analysis of PCR-amplified genomic DNA derived from
lymphoblasts and cultured dermal fibroblasts (fig. 3C).
The mutant signal was 27% and 34% of wild type in
lymphoblasts and fibroblasts, respectively, which is con-
sistent with ∼43% of lymphoblasts and ∼51% of fibro-
blasts having one R529X allele. Similar results were ob-
tained by direct incorporation of radiolabel into genomic
amplicons, after 20, 25, and 30 cycles of amplification;
subsequent restriction digestion; and direct quantifi-
cation of allele-specific signals (data not shown). Val-
ues were remarkably similar regardless of the number
of cycles and suggested that and47.0% 3.5%
of lymphoblasts and fibroblasts, respec-60.7% 3.1%
tively, harbor the mutant allele. ASO analysis of reverse-
transcription PCR–amplified cDNA from cultured fi-
broblasts showed that the mutant signal was 2% and
7% of wild type in the mother and the son, respectively
(fig. 3C). This dramatic reduction in representation of
the mutant allele can be attributed to the targeted deg-
radation of transcripts harboring a premature-termi-
nation codon by the nonsense-mediated RNA-decay
(NMRD) pathway (Dietz et al. 1993a; reviewed in Ma-
quat 1995). Immunohistochemical analysis of cultured
fibroblasts from the individual with somatic mosaicism
revealed patchy deposition, in the extracellular matrix,
of fibrils composed of fibrillin-1, when compared with
that in control cultures (fig. 4). In contrast, cultured fi-
broblasts from this individual’s son, who had inherited
the nonsense mutation by germ-line transmission,
showed nearly absent extracellular fibrillin-1 and no or-
ganized fibrils.
Discussion
Primary mutations in fibrillin-1 have been associated
with a wide range of phenotypes that show considerable
variation in the timing of onset, tissue distribution, and
severity of clinical manifestations (reviewed in Dietz and
Pyeritz 1995). Many of these conditions, such as mitral
valve prolapse syndrome, MASS phenotype, or isolated
skeletal disorders, show significant overlap with MFS
and are quite common in the general population. In or-
der to facilitate appropriate patient management and
counseling, clinical criteria for the diagnosis of MFS
were established (Beighton et al. 1988; De Paepe et al.
1996). Initial criteria (Beighton et al. 1988) proved to
be too lenient, allowing the inappropriate diagnosis of
individuals who had some manifestations of a connec-
tive-tissue disorder and a positive family history for MFS
but who lacked serious and specific manifestations of
MFS and ultimately were shown not to carry the fibrillin-
1 mutation seen in more classically affected relatives (Pe-
reira et al. 1994; Nijbroek et al. 1995). Revised diag-
nostic criteria (De Paepe et al. 1996) now require at least
one of four manifestations with major diagnostic sig-
nificance (lens dislocation, aortic dilatation or dissection,
dural ectasia, or a specified combination of skeletal fea-
tures) and involvement of at least one other system, for
MFS to be diagnosed in an individual with an unequiv-
ocally affected first-degree relative.
Although vascular disease in MFS can involve any
segment of the aorta, the root of the aorta is the most
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Figure 3 Analysis of mutation R529X. A, Sequence of PCR-amplified genomic DNA from individual II-1 (see panel B), showing a CrT
transition at nucleotide 1585 in one allele. The gene sequence and the corresponding amino acid sequence of the normal and mutant alleles in
the region of the mutation are shown (bottom), demonstrating a substitution of a termination codon (“Ter”) for arginine (“Arg”) at codon
529. B, Negative image of an ethidium bromide–stained gel, showing results of restriction analysis for mutation R529X. The appearance of
170-bp and 53-bp restriction fragments manifests the presence of the mutation. Note that the intensity of the abnormal restriction fragments
is lower in the sample from I-1, compared with that in the sample from the proband (II-1), suggesting that I-1 is a somatic mosaic. C, ASO-
hybridization analysis of PCR-amplified lymphoblast or fibroblast genomic DNA (“gDNA”) or fibroblast cDNA, from the indicated members
of the third family studied. The numbers at the bottom indicate the mutant-to–wild-type signal ratio after application of a correction factor
used to equalize the signals observed in the gDNA samples from the proband.
typical site of dilatation and dissection. The new diag-
nostic criteria take this into consideration by allowing
only dilatation that includes at least the sinuses of Val-
salva to be of “major” diagnostic significance (De Paepe
et al. 1996). This is relevant to the family shown in figure
1. The conclusion that neither child with an atypical
pattern of aortic involvement carried the same genetic
predisposition as relatives with dilatation at the sinuses
of Valsalva was validated by mutation analysis. These
individuals, who would have met the old diagnostic cri-
teria for MFS (Beighton et al. 1988), clearly need an
individualized approach to counseling and management.
Although there is ample evidence for a dominant-neg-
ative mechanism in MFS, the aspects of pathogenesis
that relate to clinical variability are poorly understood.
The majority of mutations occur within the 47 tandemly
repeated EGF-like domains of fibrillin-1, of which 43
satisfy the consensus for calcium binding (Handford et
al. 1991; Selander-Sunnerhagen et al. 1992; Corson et
al. 1993; Pereira et al. 1993). Nearly all of these mu-
tations substitute one of the six predictably spaced cys-
teine residues that interact via intradomain disulfide
linkage, one of the highly conserved residues within the
calcium-binding consensus sequence, or residues impor-
tant for interdomain hydrophobic packing interactions
(Dietz and Pyeritz 1995; Downing et al. 1996). Solving
for the solution structure of a pair of cbEGF-like do-
mains of fibrillin-1 documented that calcium binding is
required, to maintain a rigid, rodlike structure for tan-
demly repeated motifs (Downing et al. 1996; Knott et
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al. 1996). Moreover, perturbation of domain folding or
calcium binding has been shown to result in confor-
mational changes and enhanced proteolytic degradation
of single domains, recombinant peptides or intact mon-
omers, and ultrastructural changes in microfibrils (Kielty
and Shuttleworth 1993, 1994; Wu et al. 1995; Reinhardt
et al. 1997a, 1997b).
If only a handful of residues in EGF-like domains have
functional significance and are mutated in MFS, then
why are nearly all the intervening residues in human
fibrillin-1 identical in mouse, pig, and cow (Tilstra et al.
1994; Yin et al. 1995; authors’ unpublished data)? With
one exception, the few mutations in these intervening
regions of EGF-like domains of fibrillin-1 involve cys-
teine, proline, or glycine residues and therefore are pre-
dicted, or have been proved, to alter domain folding
(Dietz and Pyeritz 1995; Wu et al. 1995; Downing et al.
1996). The remaining, and potentially most interesting,
mutation (R1170H) falls in a variable loop region and
was shown to cosegregate with an isolated skeletal phe-
notype in a small family (Hayward et al. 1994). It has
been postulated that such a mutation allows the depo-
sition of stable microfibrils with relatively preserved
structure and function (Hayward et al. 1994; Downing
et al. 1996). We now have shown that R1170H cosegre-
gates with disease in a second family displaying a phe-
notype that predominantly involves the skeleton. These
data suggest that residues within the variable loop
regions of EGF-like domains in fibrillin-1 have func-
tional significance and that events modulated by R1170,
within the EGF-like domain encoded by FBN1 exon 28,
influence skeletal growth.
In the third family, the individual who had inherited
R529X through germ-line transmission displayed a clas-
sic and severe MFS phenotype, despite the marked de-
crease in mutant-transcript abundance induced by this
nonsense mutation. Nonsense mutations in FBN1 and
many other genes have been shown to induce mutant-
transcript degradation, through NMRD (Dietz et al.
1993a; reviewed in Maquat 1995). Selected FBN1 non-
sense alleles have been shown to be associated with mild
phenotypes, whereas others have been shown to produce
severe disease (Dietz et al. 1993a, 1993b; Aoyama et al.
1994). The genotype-specific efficiency of NMRD has
been proposed to be the discriminating factor. It has been
suggested that mutant-transcript levels 10% of wild
type may produce a protein sufficiently truncated to al-
low dominant-negative interference with the utilization
of protein derived from the wild-type allele. Thus far,
the 7% level of mutant transcript seen with R529X is
the lowest to be associated with severe MFS. Immuno-
histochemical analysis of cultured dermal fibroblasts
from the patient heterozygous for R529X showed a near
absence of extracellular fibrillin-1. It is unclear whether
this finding manifests dominant-negative activity of a
trivial level of mutant protein or a protein concentra-
tion–dependent perturbation of matrix utilization of
product from the wild-type allele.
It was very interesting to note the extremely mild phe-
notype observed in indivudual I-1 (fig. 3), who is a so-
matic mosaic for a fibrillin-1 mutation. The clinical sam-
ples only showed the mutation in ∼50% of cells.
Documented involvement of such embryologically di-
verse tissues as peripheral blood leukocytes, dermal fi-
broblasts, and the germ line suggests that all tissues are
similarly affected. Immunohistochemical analysis of cul-
tured dermal fibroblasts showed patchy deposition of
extracellular fibrillin-1. These data have implications for
gene therapy for this disorder, suggesting that 50% of
cells would need to be corrected, to achieve a significant
therapeutic benefit.
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